H.R.2022 - LATTS Act of 2017115th Congress (2017-2018) |
|Sponsor:||Rep. Gosar, Paul A. [R-AZ-4] (Introduced 04/06/2017)|
|Committees:||House - Energy and Commerce|
|Latest Action:||House - 04/07/2017 Referred to the Subcommittee on Health. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed House
- Passed Senate
- To President
- Became Law
Summary: H.R.2022 — 115th Congress (2017-2018)All Information (Except Text)
Introduced in House (04/06/2017)
Label and Transport Tissues Safely Act of 2017 or the LATTS Act of 2017
This bill prohibits the sale of human tissue for research or education unless the seller has a non-transplant tissue bank license, each package of tissue is labeled with specified information, and each package is wrapped in the prescribed manner.
The Department of Health and Human Services (HHS) shall establish a process for the approval, suspension, and revocation of non-transplant tissue bank licenses.
False labeling of packages of human tissue is prohibited.
HHS or any accrediting body authorized by HHS is allowed to enter and inspect any facility that is subject to a non-transplant tissue bank license.
HHS shall recall any human tissue specimen that is an imminent or substantial hazard to public health.
The bill makes it unlawful to knowingly sell or otherwise transfer any human tissue specimen if the transfer affects interstate commerce.